Literature DB >> 21357779

Primary intracranial leiomyosarcoma in an immunocompetent adult.

Narothama Reddy Aeddula1, Samata Pathireddy, Tony Samaha, Thomas Ukena, Alireza Hosseinnezhad.   

Abstract

Entities:  

Mesh:

Year:  2011        PMID: 21357779     DOI: 10.1200/JCO.2010.33.4805

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


× No keyword cloud information.
  6 in total

1.  Primary Leiomyosarcoma of the Calvarium with Intracranial Extension: a Case Report.

Authors:  Amade Bregy; Jaims Lim; Robert Lohman; John Kane; Dheerendra Prasad; Jingxin Qiu; Robert A Fenstermaker
Journal:  Indian J Surg Oncol       Date:  2020-07-01

2.  Pazopanib-mediated Long-term Disease Stabilization after Local Recurrence and Distant Metastasis of Primary Intracranial Leiomyosarcoma: A Case Report on the Efficacy of Pazopanib as a Salvage Therapy.

Authors:  Yasuhiro Kawabata; Tomokazu Aoki; Tetsurou Yamamoto; Hisateru Yasui; Satoru Sawai; Shunichi Fukuda; Satoru Kawarazaki; Tetsuya Tsukahara
Journal:  NMC Case Rep J       Date:  2017-12-07

3.  Primary intracranial leiomyosarcoma in an immunocompetent patient: Case report with emphasis on imaging features.

Authors:  Xiu-Li Li; Jing Ren; Run-Ning Niu; Xiao Jiang; Guo-Hui Xu; Peng Zhou; Zhu-Zhong Cheng
Journal:  Medicine (Baltimore)       Date:  2019-04       Impact factor: 1.817

4.  Primary intracranial leiomyosarcoma presenting with massive peritumoral edema and mass effect: Case report and literature review.

Authors:  Sachidanand Gautam; Rajesh K Meena
Journal:  Surg Neurol Int       Date:  2017-11-20

5.  Low-grade Leiomyosarcoma of the Cavernous Sinus in an HIV Positive Patient: Case Report.

Authors:  Laura Morales R; Angelina Álvarez; Maria Paulina Noreña; Felipe Torres; José Esguerra
Journal:  Cureus       Date:  2020-01-23

6.  Primary Intracranial Leiomyosarcoma Secondary to Glioblastoma: Case Report and Literature Review.

Authors:  Liyan Zhao; Yining Jiang; Yubo Wang; Yang Bai; Ying Sun; Yunqian Li
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.